Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice - 09/12/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Adrenomedullin and GLP-1 shows additive effects on acute food intake in mice.
Highlights |
• | Adrenomedullin reduces acute food intake in mice. |
• | Adrenodemullin and GLP-1 show additive effects on food intake. |
• | GLP-1 prevents adrenodemullin induced insulin release. |
Abstract |
Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, and central administration of ADM has been shown to elicit anorexigenic effects. Here, we investigated if peripheral co-administration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while enhancing its anorectic properties.
The effects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose homeostasis were assessed acutely in male NMRI mice for 12 h, while effects on glucose homeostasis were assessed by oral glucose tolerance tests (OGTT).
While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic effects, co-administration of the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glucose-excursions were significantly increased by ADM monotherapy, co-administration of ADM with a lower dose of GLP-1 normalized glucose excursions.
In conclusion, we demonstrate additive anorectic effects of ADM and GLP-1, and that GLP-1 co-administration prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity target when combined with GLP-1 agonist therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Adrenomedullin, ADM, Food intake, Insulin secretion, Glucose tolerance, Obesity, Diabetes, Glucagon-like peptide 1, GLP-1
Plan
Vol 109
P. 167-173 - janvier 2019 Retour au numéro
Article précédent
- In vitro anti-Trypanosoma cruzi activity of ternary copper(II) complexes and in vivo evaluation of the most promising complex
- Drielly A. Paixão, Carla D. Lopes, Zumira A. Carneiro, Luana M. Sousa, Leticia P. de Oliveira, Norberto P. Lopes, Marcos Pivatto, Joana Darc S. Chaves, Mauro V. de Almeida, Javier Ellena, Mariete B. Moreira, Adelino V.G. Netto, Ronaldo J. de Oliveira, Silvana Guilardi, Sérgio de Albuquerque, Wendell Guerra
- Association between catatonia and levels of hair and serum trace elements and minerals in autism spectrum disorder
- Alexey A. Tinkov, Margarita G. Skalnaya, Natalia V. Simashkova, Tatiana P. Klyushnik, Anastasia A. Skalnaya, Geir Bjørklund, Svetlana V. Notova, Elena V. Kiyaeva, Anatoly V. Skalny
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?